Navigation Links
Medivation Announces New Positive Efficacy Data From Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients
Date:2/25/2009

- MDV3100 Consistently Demonstrates Anti-Tumor Activity Across Doses and Endpoints in both Chemotherapy Naive and Post-Chemotherapy Patients -

- Data To Be Presented at ASCO's 2009 Genitourinary Cancers Symposium -

- Medivation to Host Conference Call and Webcast Presentation with Dr. Howard Scher Today at 4:30 p.m. Eastern Time -

SAN FRANCISCO, Feb. 25 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced the presentation of new efficacy and safety data from an ongoing Phase 1-2 clinical trial of the Company's novel androgen receptor antagonist MDV3100 in castration-resistant prostate cancer (CRPC) patients. The new efficacy data cover all 114 patients who have been followed for 12 weeks or longer, and show that MDV3100 consistently demonstrated encouraging anti-tumor activity across dose levels and endpoints.

"The data thus far suggest a favorable benefit/risk ratio for MDV3100 in treating castration-resistant prostate cancer patients," said Howard Scher, M.D., principal investigator of the trial and chief of the Genitourinary Oncology Service and the D. Wayne Calloway Chair in Urologic Oncology at Memorial Sloan-Kettering Cancer Center. "These men have a limited life expectancy, and currently their only approved treatment option is chemotherapy. Given these encouraging results and the large unmet medical need for men with castration-resistant prostate cancer, I am enthusiastic about working with Medivation to advance MDV3100 into Phase 3 clinical development this year."

All patients had progressive disease upon enrollment and were heavily pretreated, with 77 percent having failed at least two lines of prior hormonal therapy and 43 percent having also failed one or more chemotherapy regimens. Efficacy endpoints in the study included circulating tumor
'/>"/>

SOURCE Medivation, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Medivation Presents New Data on Dimebons Novel Mechanism of Action
2. Medivation Announces Participation in RBC Capital Markets 2008 Healthcare Conference
3. Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update
4. Medivation Announces Third Quarter 2008 Teleconference and Webcast on November 10, 2008
5. Medivation Announces Expiration of Hart-Scott-Rodino Waiting Period for Collaboration With Pfizer
6. Medivation Announces Presentation of 24-Week Clinical Data of MDV3100 in Castration-Resistant Prostate Cancer Patients
7. Medivation Receives Corporate Achievement Award From Huntingtons Disease Society of America
8. Medivation to Host Conference Call at 8:30 a.m. Eastern Time Tomorrow to Discuss Partnering Plans for Dimebon
9. Medivation Announces Participation in Upcoming Conferences
10. Medivation Reports Second Quarter 2008 Financial Results and Provides Corporate Update
11. Medivation Announces Second Quarter 2008 Teleconference and Webcast on August 11, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... MA (PRWEB) May 05, 2015 The ... ), a Massachusetts-based non-profit operating in the public interest, ... affiliate of the Hearst Communications Company, have formed a ... for public outreach and education across the healthcare and ... for the voice of patients and the public to ...
(Date:5/4/2015)... , May 4, 2015 Tobira Therapeutics, ... on the development and commercialization of novel treatments ... completion of its merger with Regado Biosciences, Inc. ... the closing of the merger, Tobira raised $40 ... new investors and all current Tobira institutional investors, ...
(Date:5/4/2015)... May 4, 2015   St. Jude Children,s ... better computer tool for finding genetic alterations that ... were difficult to identify with whole-genome sequencing. The ... Nature Methods . The tool is ... Segmentation by Regression Tree in Next Generation Sequencing. ...
(Date:5/4/2015)... Israel , May 4, 2015  Tikcro Technologies ... its annual report on Form 20-F for the fiscal ... and Exchange Commission ("SEC"). The annual report on Form ... development of antibodies in the area of cancer immune ... superior qualities of high specificity and binding in targeting ...
Breaking Biology Technology:ACRES and San Antonio Express-News Launch Blog on Accountability in Clinical Research 2ACRES and San Antonio Express-News Launch Blog on Accountability in Clinical Research 3ACRES and San Antonio Express-News Launch Blog on Accountability in Clinical Research 4Tobira Therapeutics Completes Financing and Merger with Regado Biosciences 2Tobira Therapeutics Completes Financing and Merger with Regado Biosciences 3Tobira Therapeutics Completes Financing and Merger with Regado Biosciences 4Tobira Therapeutics Completes Financing and Merger with Regado Biosciences 5Tobira Therapeutics Completes Financing and Merger with Regado Biosciences 6Scientists dramatically improve method for finding common genetic alterations in tumors 2Scientists dramatically improve method for finding common genetic alterations in tumors 3Scientists dramatically improve method for finding common genetic alterations in tumors 4Tikcro Technologies Files Annual Report on Form 20-F for the Year Ended December 31, 2014 2
... Toronto Stock Exchange Symbol: MS , ... EDMONTON, AB , ... today announced its updated corporate strategy. The Company,s new strategy ... industry, whereby BioMS will directly invest in and advise companies ...
... , May 3 The Global Alliance for ... the 2010 BIO International Convention that they have entered into ... clinical use of drugs against tuberculosis (TB), including drug resistant ... are resistant to at least one of today,s standard first-line ...
... , WALTHAM, Mass. , May 3 Interleukin ... Lewis H. Bender will moderate and co-present a panel ... Development: How to Improve Efficacy and Commercial Success" at the BIO ... Chicago, IL.  The panel discussion will be held Wednesday, ...
Cached Biology Technology:BioMS updates corporate strategy and adds leading healthcare investment banker 2BioMS updates corporate strategy and adds leading healthcare investment banker 3TB Alliance and AstraZeneca Form Research Collaboration to Fight Tuberculosis 2TB Alliance and AstraZeneca Form Research Collaboration to Fight Tuberculosis 3TB Alliance and AstraZeneca Form Research Collaboration to Fight Tuberculosis 4Interleukin Genetics to Present at Upcoming Biotech Industry Meetings 2
(Date:4/17/2015)... Increasing adoption in ... to drive biometric systems market in ... According to a recently released TechSci Research ... biometric systems market in Saudi Arabia ... CAGR of over 22% through 2020. The market ...
(Date:4/10/2015)... , April 10, 2015 ... addition of the "Security Competitive Profiles - NEC" ... http://photos.prnewswire.com/prnh/20130307/600769) , NEC will continue to supply ... to the market, with a company focus on the ... anticipated. Winning opportunities in the ...
(Date:4/2/2015)... 2015 At its 2015 ACMG Annual Clinical ... , the American College of Medical Genetics and Genomics ... its Board.  Members of the ACMG Board of Directors ... and advancing its policies and programs. ACMG is the ... "It,s an eventful time in medical genetics and genomics.  ...
Breaking Biology News(10 mins):Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3NEC Security Competitive Profile 2015 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8
... or go extinct as a result of climate change, grasslands ... to defy the odds and adapt to long-term changes in ... from Syracuse University and the University of Sheffield (United Kingdom) ... Edition of the Proceedings of the National Academy of ...
... WASHINGTON, DC, JULY 7, 2008 -- The Soil Science ... by Senator Sherrod Brown and his colleagues in the ... as an "essential" natural resource, placing soil on par ... Brown was joined by co-sponsoring Senators Kent Conrad (D-ND), ...
... joining the trend to go green. Chemical engineering researchers ... in our bodies can be used as a natural moisturizing ... from the current wave of self-moisturizing contact lenses that use ... and increase wearer comfort. It is estimated that more ...
Cached Biology News:New study finds that some plants can adapt to widespread climate change 2Senate resolution shines spotlight on the importance of soils 2Self-moisturizing contact lenses, naturally 2
... The Oxidized LDL Competitive ELISA is based ... the sample competes with a fixed amount of ... the binding of the biotin- labeled specific antibodies. ... 25 l The Oxidized LDL Competitive Enzyme-Linked Immunosorbent ...
... ShortCut RNase III, used with its manganese-containing ... a heterogeneous mix of short (1825 bp) ... in mammalian cells. 1.3 units (1 l) ... convert 1 g of dsRNA into siRNA ...
For cleavage of 6xHis tags from proteins containing a Factor Xa Protease recognition site Efficient 6xHis tag cleavage (greater than 90%), ...
... PBL's bioassays for interferons are cytopathic effect ... assays. Sample types include; tissue culture supernatents; ... In these assays, one unit is defined as ... reduce the cytopathic effect of viral infection by ...
Biology Products: